Our guest today is Nolan Townsend, the CEO of LEXEO Therapeutics, which focused on expanding the application of crisper gene therapies past rare diseases where they’ve generally been applied to more prevalent kinds of diseases.
What got me excited for the talk was the enthusiasm that Nolan expressed for the application of genetic therapies to more common diseases, which is where all the costs live. This could have a very broad impact on society’s healthcare systems.

Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Ver todos los episodios